Drugs / XP21279
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00914602 | May 2009 → Jan 2010 | Parkinson disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01171313 | Jul 2010 → Oct 2011 | Parkinson disease | XenoPort, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP21279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01171313 ↗ |